Biotech Firm Sirnaomics Targets up to $70.3m in Hong Kong IPO
This article is for subscribers only.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, is offering 7.54 million shares at HK$65.9-HK$72.7 apiece in its Hong Kong initial public offering, the company said in a statement Sunday.
The drug maker, which has presence in both China and the U.S., may raise up to HK$548.2 million ($70.3 million) from the listing, according to Bloomberg calculations.